Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2010 3
2011 3
2012 5
2013 4
2014 3
2016 3
2017 2
2018 3
2019 3
2020 2
2021 3
2022 2
2023 3
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

35 results

Results by year

Filters applied: . Clear all
Page 1
De-Escalated Neoadjuvant Trastuzumab-Emtansine With or Without Endocrine Therapy Versus Trastuzumab With Endocrine Therapy in HR+/HER2+ Early Breast Cancer: 5-Year Survival in the WSG-ADAPT-TP Trial.
Harbeck N, Nitz UA, Christgen M, Kümmel S, Braun M, Schumacher C, Potenberg J, Tio J, Aktas B, Forstbauer H, Grischke EM, Scheffen I, Malter W, von Schumann R, Just M, Zu Eulenburg C, Biehl C, Kolberg-Liedtke C, Deurloo R, de Haas S, Jóźwiak K, Hauptmann M, Kates R, Graeser M, Wuerstlein R, Kreipe HH, Gluz O; WSG-ADAPT investigators. Harbeck N, et al. Among authors: zu eulenburg c. J Clin Oncol. 2023 Aug 1;41(22):3796-3804. doi: 10.1200/JCO.22.01816. Epub 2023 Feb 21. J Clin Oncol. 2023. PMID: 36809046 Clinical Trial.
De-escalated neoadjuvant pertuzumab plus trastuzumab therapy with or without weekly paclitaxel in HER2-positive, hormone receptor-negative, early breast cancer (WSG-ADAPT-HER2+/HR-): survival outcomes from a multicentre, open-label, randomised, phase 2 trial.
Nitz U, Gluz O, Graeser M, Christgen M, Kuemmel S, Grischke EM, Braun M, Augustin D, Potenberg J, Krauss K, Schumacher C, Forstbauer H, Reimer T, Stefek A, Fischer HH, Pelz E, Zu Eulenburg C, Kates R, Wuerstlein R, Kreipe HH, Harbeck N; WSG-ADAPT investigators. Nitz U, et al. Among authors: zu eulenburg c. Lancet Oncol. 2022 May;23(5):625-635. doi: 10.1016/S1470-2045(22)00159-0. Epub 2022 Apr 8. Lancet Oncol. 2022. PMID: 35405088 Clinical Trial.
Nab-paclitaxel weekly versus dose-dense solvent-based paclitaxel followed by dose-dense epirubicin plus cyclophosphamide in high-risk HR+/HER2- early breast cancer: results from the neoadjuvant part of the WSG-ADAPT-HR+/HER2- trial.
Gluz O, Kuemmel S, Nitz U, Braun M, Lüdtke-Heckenkamp K, von Schumann R, Darsow M, Forstbauer H, Potenberg J, Uleer C, Grischke EM, Aktas B, Schumacher C, Zu Eulenburg C, Kates R, Jóźwiak K, Graeser M, Wuerstlein R, Baehner R, Christgen M, Kreipe HH, Harbeck N. Gluz O, et al. Among authors: zu eulenburg c. Ann Oncol. 2023 Jun;34(6):531-542. doi: 10.1016/j.annonc.2023.04.002. Epub 2023 Apr 14. Ann Oncol. 2023. PMID: 37062416 Clinical Trial.
De-escalated Neoadjuvant Chemotherapy in Early Triple-Negative Breast Cancer (TNBC): Impact of Molecular Markers and Final Survival Analysis of the WSG-ADAPT-TN Trial.
Gluz O, Nitz U, Kolberg-Liedtke C, Prat A, Christgen M, Kuemmel S, Mohammadian MP, Gebauer D, Kates R, Paré L, Grischke EM, Forstbauer H, Braun M, Warm M, Hackmann J, Uleer C, Aktas B, Schumacher C, Wuerstlein R, Graeser M, Pelz E, Jóźwiak K, Zu Eulenburg C, Kreipe HH, Harbeck N; ADAPT TN investigators. Gluz O, et al. Among authors: zu eulenburg c. Clin Cancer Res. 2022 Nov 14;28(22):4995-5003. doi: 10.1158/1078-0432.CCR-22-0482. Clin Cancer Res. 2022. PMID: 35797219
Impact of RNA Signatures on pCR and Survival after 12-Week Neoadjuvant Pertuzumab plus Trastuzumab with or without Paclitaxel in the WSG-ADAPT HER2+/HR- Trial.
Graeser M, Gluz O, Biehl C, Ulbrich-Gebauer D, Christgen M, Palatty J, Kuemmel S, Grischke EM, Augustin D, Braun M, Potenberg J, Wuerstlein R, Krauss K, Schumacher C, Forstbauer H, Reimer T, Stefek A, Fischer HH, Pelz E, Zu Eulenburg C, Kates R, Ni H, Kolberg-Liedtke C, Feuerhake F, Kreipe HH, Nitz U, Harbeck N. Graeser M, et al. Among authors: zu eulenburg c. Clin Cancer Res. 2023 Feb 16;29(4):805-814. doi: 10.1158/1078-0432.CCR-22-1587. Clin Cancer Res. 2023. PMID: 36441798 Free PMC article. Clinical Trial.
Duodenal Electric Stimulation: Results of a First-in-Man Study.
Aberle J, Busch P, Veigel J, Duprée A, Roesch T, zu Eulenburg C, Paschen B, Scholz BM, Wolter S, Sauer N, Ludwig K, Izbicki J, Mann O. Aberle J, et al. Among authors: zu eulenburg c. Obes Surg. 2016 Feb;26(2):369-75. doi: 10.1007/s11695-015-1774-8. Obes Surg. 2016. PMID: 26112135
Pregnancy in primary sclerosing cholangitis.
Wellge BE, Sterneck M, Teufel A, Rust C, Franke A, Schreiber S, Berg T, Günther R, Kreisel W, Zu Eulenburg C, Braun F, Beuers U, Galle PR, Lohse AW, Schramm C. Wellge BE, et al. Among authors: zu eulenburg c. Gut. 2011 Aug;60(8):1117-21. doi: 10.1136/gut.2010.228924. Epub 2011 Feb 21. Gut. 2011. PMID: 21339205
TP53 mutations are associated with primary endocrine resistance in luminal early breast cancer.
Grote I, Bartels S, Kandt L, Bollmann L, Christgen H, Gronewold M, Raap M, Lehmann U, Gluz O, Nitz U, Kuemmel S, Zu Eulenburg C, Braun M, Aktas B, Grischke EM, Schumacher C, Luedtke-Heckenkamp K, Kates R, Wuerstlein R, Graeser M, Harbeck N, Christgen M, Kreipe H. Grote I, et al. Among authors: zu eulenburg c. Cancer Med. 2021 Dec;10(23):8581-8594. doi: 10.1002/cam4.4376. Epub 2021 Nov 14. Cancer Med. 2021. PMID: 34779146 Free PMC article.
Pelvic Lymphadenectomy in Vulvar Cancer - Does it make sense?
Woelber L, Bommert M, Prieske K, Fischer I, Zu Eulenburg C, Vettorazzi E, Harter P, Jueckstock J, Hilpert F, de Gregorio N, Iborra S, Sehouli J, Ignatov A, Hillemanns P, Fuerst S, Strauss HG, Baumann K, Beckmann M, Mustea A, Meier W, Wimberger P, Hanker L, Canzler U, Fehm T, Luyten A, Hellriegel M, Kosse J, Heiss C, Hantschmann P, Mallmann P, Tanner B, Pfisterer J, Mahner S, Schmalfeldt B, Jaeger A. Woelber L, et al. Among authors: zu eulenburg c. Geburtshilfe Frauenheilkd. 2020 Dec;80(12):1221-1228. doi: 10.1055/a-1120-0138. Epub 2020 Dec 3. Geburtshilfe Frauenheilkd. 2020. PMID: 33293730 Free PMC article.
35 results